(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 39.19% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Eton Pharmaceuticals's revenue in 2026 is $86,934,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $3,371,177,499, with the lowest ETON revenue forecast at $3,224,354,460, and the highest ETON revenue forecast at $3,485,951,479. On average, 5 Wall Street analysts forecast ETON's revenue for 2027 to be $4,999,379,259, with the lowest ETON revenue forecast at $4,764,078,903, and the highest ETON revenue forecast at $5,188,660,452.
In 2028, ETON is forecast to generate $6,379,680,178 in revenue, with the lowest revenue forecast at $5,905,792,385 and the highest revenue forecast at $6,807,000,963.